Aaro Haapaniemi1, Janne Väisänen2,3,4, Timo Atula1, Olli-Pekka Alho2,3,4, Antti Mäkitie1, Petri Koivunen2,3,4. 1. Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 2. Department of Otorhinolaryngology - Head and Neck Surgery, Oulu University Hospital, Oulu, Finland. 3. PEDEGO Research Unit, University of Oulu, Oulu, Finland. 4. Medical Research Center Oulu, Oulu, Finland.
Abstract
BACKGROUND: Up to 30% of patients with laryngeal squamous cell carcinoma (SCC) present with recurrence after treatment. We analyzed factors associated with the risk of cancer recurrence and prognosis after recurrence. METHODS: A nationwide laryngeal SCC cohort from Finnish university hospitals during 2001 to 2005 with initial successful therapy (n = 316) was analyzed. RESULTS: Laryngeal SCC recurred in 22% of patients. The median time to recurrence was 9 months, with 90% occurring within 36 months after treatment. The World Health Organization (WHO) performance status >0, neck metastasis at presentation, and nonsurgical treatment were independent prognostic factors for recurrence. Patients with local recurrence had a 5-year overall survival (OS) of 53% compared with 5% in patients with regional/distant recurrences. OS for glottic and nonglottic laryngeal SCC recurrence was 45% and 0%, respectively. CONCLUSION: The type of treatment affected the risk of recurrence in this retrospective series. Local recurrences carried a chance for successful salvage treatment. Routine follow-up beyond 36 months remains controversial.
BACKGROUND: Up to 30% of patients with laryngeal squamous cell carcinoma (SCC) present with recurrence after treatment. We analyzed factors associated with the risk of cancer recurrence and prognosis after recurrence. METHODS: A nationwide laryngeal SCC cohort from Finnish university hospitals during 2001 to 2005 with initial successful therapy (n = 316) was analyzed. RESULTS: Laryngeal SCC recurred in 22% of patients. The median time to recurrence was 9 months, with 90% occurring within 36 months after treatment. The World Health Organization (WHO) performance status >0, neck metastasis at presentation, and nonsurgical treatment were independent prognostic factors for recurrence. Patients with local recurrence had a 5-year overall survival (OS) of 53% compared with 5% in patients with regional/distant recurrences. OS for glottic and nonglottic laryngeal SCC recurrence was 45% and 0%, respectively. CONCLUSION: The type of treatment affected the risk of recurrence in this retrospective series. Local recurrences carried a chance for successful salvage treatment. Routine follow-up beyond 36 months remains controversial.
Authors: Ximena Mimica; Martin Hanson; Snehal G Patel; Marlena McGill; Sean McBride; Nancy Lee; Lara A Dunn; Jennifer R Cracchiolo; Jatin P Shah; Richard J Wong; Ian Ganly; Marc A Cohen Journal: Head Neck Date: 2019-08-21 Impact factor: 3.147
Authors: Lilian N Ruiter; Boukje A C van Dijk; Annette H Bruggink; Patricia A H Doornaert; Marielle E P Philippens; Remco de Bree; Carla H van Gils; Stefan M Willems Journal: BMC Cancer Date: 2022-04-22 Impact factor: 4.638